Civil Society Groups Bar The Way To Hepatitis C Patents

Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents
10/05/2018 by Catherine Saez, Intellectual Property Watch

Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need.

Continue reading: http://www.ip-watch.org/2018/05/10/collective-efforts-civil-society-groups-bar-way-hepatitis-c-patents/